Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (151,197)	$ (43,859)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	31,995	12,250
Stock-based compensation expense	6,968	11,145
Noncash research and development expense (finance lease)	0	434
Noncash operating lease expense	11,908	14,966
Gain from sale of priority review voucher	0	(92,930)
Excess inventory reserve	5,666	6,278
Noncash interest related to debt	1,004	0
Other non-cash items	(21)	343
Gain on foreign currency exchange rates	(581)	(281)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(35,131)	(6,440)
Inventory	(15,729)	(17,599)
Accounts payable	12,517	(5,623)
Accrued expenses and other liabilities	(5,670)	3,052
Accrued interest payable under finance lease	5,646	819
Operating lease liabilities	(8,303)	(13,276)
Deferred revenue	0	(138)
Net cash used in operating activities	(140,928)	(130,859)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,834)	(937)
Purchases of marketable securities	0	(34,418)
Proceeds from previously transferred invoices	2,800	0
Proceeds from maturities of marketable securities	0	26,521
Proceeds from sales of marketable securities	0	5,853
Purchase of intangible assets	0	(868)
Proceeds from sale of priority review voucher	0	92,930
Net cash provided by investing activities	966	89,081
Cash flows from financing activities:
Proceeds from the issuance of debt, net of fees paid to lender	71,316	0
Proceeds allocated to detachable warrants issued in conjunction with debt	2,669	0
Payments of debt issuance costs	(2,576)	0
Proceeds from exercise of stock options and ESPP contributions	0	85
Proceeds from the transfer of invoices	35,820	0
Principal payments on finance leases	(48,645)	(28,504)
Net cash provided by financing activities	58,584	101,507
(Decrease) increase in cash, cash equivalents and restricted cash	(81,378)	59,729
Cash, cash equivalents and restricted cash at beginning of period	274,597	158,445
Cash, cash equivalents and restricted cash at end of period	193,219	218,174
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	144,067	172,872
Restricted cash included in other current assets	1,154	1,364
Restricted cash included in restricted cash and other non-current assets	47,998	43,938
Total cash, cash equivalents and restricted cash	193,219	218,174
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses	284	2,290
Right-of-use assets obtained in exchange for financial lease liabilities	43,055	3,436
Cash paid (refund received) during the period for income taxes	(10)	7
Beneficiary interest obtained in transferred invoices	3,680	0
Derecognition of due to factor liabilities	33,120	0
Private Placement
Cash flows from financing activities:
Proceeds from issuance of common stock	0	(196)
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	$ 130,122